MarketBeat Week in Review – 10/7 - 10/11Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't IgnoreCheck out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQSKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE.
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQSKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE.
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or “the Company”) (
NASDAQSKYE) for violations of the securities laws.
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for ObesityBOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational neurodiagnostics, today announced a strategic collaboration with Skye Bioscience, Inc. (Nasdaq: SKYE), a pharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, to enhance its upcoming CBEYOND™ Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity.
